Injectable Drug Delivery: A 2-Day Seminar Presented by Experts (London, UK - March 18-19, 2020)
DUBLIN, Jan. 27, 2020 /PRNewswire/ -- The "Injectable Drug Delivery" conference has been added to ResearchAndMarkets.com's offering.
This seminar has been designed to provide all those working in the industry with the latest information on the next generation of injectable drugs and devices and an update on recent trends, technologies and applications. It will also be a great opportunity to meet industry leaders, as well as like-minded professionals, and share common experience and best practice.
Attending this two-day seminar, presented by experts in the field, will:
Give you a valuable update on the advances in injection technology and drug delivery
Present you with up-to-date information on the latest market trends and opportunities for your organisation
Provide you with an opportunity to develop significant business partnerships
Injectable drug delivery is considered to be one of the most effective routes of administration due to the speed and effectiveness of delivery to the target, and recent developments have improved the patient experience.
The global injectable drug delivery market continues to grow and technology is advancing. This, coupled with the ever-changing regulatory requirements, means that it is imperative for companies to stay abreast of the latest developments and challenges within the industry in order to remain compliant, as well as gaining a competitive edge.
Agenda
Programme Day One
Devices, technology, and latest trends
Latest developments for injectable drug delivery solutions
Market overview and trends
How can a science-driven CDMO help to accelerate developments for biologics? - Case study Dr Thomas Schoenknecht
Recent advances in large-volume injection
Large-volume autoinjectors
Patch injectors
Latest usability insights into autoinjector and patch injector systems Ian Thompson
Discussion session
Developments in technology with injectables - digitalisation and smart technology
Internet of me' - connected drug delivery advances
Sustainable patient engagement for better outcomes
Market forces and business drivers Neil Williams
Digital design in the development of injectable systems
Hardware and software solutions
Integration into the connected ecosystem
Device management trends Markus Bauss
Discussion session
Case study: Connected needle-free technology
Adherence to treatment in injectable therapies for chronic disease is very low
Opportunities with a new form of drug delivery that is needle-free
Transforming the perception and approachability of therapies based on injectable biologics
Next-gen needle-free drug delivery platform that is computer-controlled - Supporting patient needs
Clinical and market studies - results and findings Patrick Anquetil
Patient considerations and design processes
Assessing injection site pain
Understanding how to measure pain and tolerability during injection and how to interpret the results
Summary of recent clinical investigations
Impact on the design and selection of drug delivery devices Chris Muenzer
Discussion session
Betwixt and between - managing the interface between PFS and autoinjector
Understanding the physical interface between PFS and autoinjector
A framework for ensuring compatibility across the interface
Working together in harmony - the organisational interface between pharma, syringe manufacturer and device developer Dr Jeffrey Philippson
Interactive panel discussion: Next-generation innovations in drug delivery Moderator: Dr Gregory Berman Panellists: Ian Thompson, Neil Williams, Markus Bauss, Dr Thomas Schoenknecht
Drinks reception
Programme Day Two
Regulatory update and human factors
The EU regulatory framework for injectable delivery systems
Deciding on your regulatory strategy
Implications of the Medical Device Regulation (EU) 2017/74 and Article 117 for drug delivery systems
Classification - the importance of getting it right from the start
Combination products - drug/device, device/drug?
Essential considerations for injectable medicinal products
Brexit implications Dr David Jefferys
Human factors validation - when is usability testing not required?
Overview of regulatory guidelines covering human factors for combination products - Considerations for determining if a study will be required
Utilising comparative analyses
Approaches to compiling supporting evidence Lee Wood
Discussion session
Sustainability - its impact on self-care drug delivery
The circular economy
Sustainability and the pharma industry Gregor Anderson
Packaging and quality
Extractables and leachables (E&L) in injectable drug products
The ongoing evolution of thresholds for control of E&L in drug products Raphael Nudelman
Discussion session
Pre-filled syringes in a nutshell
The components
The building blocks
Potential options
Lure-tip syringes, dual-chamber pre-filled syringes and staked-in needles
How everything comes together Dr Andreas Rothmund
The relationship between the ICH guidelines for impurities and E&L thresholds
ICH guidelines for impurities and non-mutagenic impurities
Principles from the ICH guidelines for impurities that can be used for the risk assessment of E&L in drug products Raphael Nudelman
Interactive panel discussion: The future with smart injection devices Moderator: Dr Gregory Berman Panellists: Ian Thompson and Dr Thomas Schoenknecht
Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced it granted an inducement award on March 28, 2024.
One individual was...
Paladin Labs Inc., a subsidiary of Endo International plc , today announced Health Canada's approval of WAKIX® (pitolisant hydrochloride tablets) for the treatment of excessive daytime sleepiness (EDS) or cataplexy in pediatric patients aged 6 years...
Sirona Biochem Corp. ("Sirona") announces the voting results from its Annual General Meeting of Shareholders (the "Meeting"), held in Vancouver, British Columbia on March 28, 2024. The total number of shares represented by shareholders present in...
The Doctors Company, the nation's largest physician-owned medical malpractice insurer, announced today that it has approved a 2024 premium dividend of approximately $14.7 million, bringing the total of declared dividends to date to $470 million....
Northern Virginia Oral, Maxillofacial & Implant Surgery ("NOVA OMS") has learned of a data security incident that may have impacted data belonging to certain patients and guarantors.
On October 5, 2023, NOVA OMS became aware of unusual activity on...
The Journey Venture Studio announced today a strategic collaboration with Valleywise Health, a comprehensive healthcare system with locations throughout the Phoenix metro area. In pursuit of fostering innovation, this collaboration is set to...